Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells $24,501.14 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,153 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $11.38, for a total transaction of $24,501.14. Following the completion of the sale, the insider now directly owns 195,840 shares of the company’s stock, valued at approximately $2,228,659.20. This represents a 1.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Oxana Beskrovnaya also recently made the following trade(s):

• On Tuesday, February 18th, Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10.

Dyne Therapeutics Trading Up 1.4 %

Shares of Dyne Therapeutics stock opened at $12.05 on Friday. The company has a 50 day moving average of $14.58 and a 200-day moving average of $25.27. Dyne Therapeutics, Inc. has a 1-year low of $11.18 and a 1-year high of $47.45. The company has a market cap of $1.36 billion, a PE ratio of -3.38 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of New Jersey Common Pension Fund D acquired a new position in Dyne Therapeutics in the 3rd quarter valued at approximately $1,588,000. Jennison Associates LLC lifted its stake in shares of Dyne Therapeutics by 1.5% in the third quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock valued at $48,383,000 after buying an additional 19,730 shares in the last quarter. abrdn plc bought a new position in shares of Dyne Therapeutics in the fourth quarter valued at $608,000. RA Capital Management L.P. boosted its holdings in Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after purchasing an additional 331,940 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Dyne Therapeutics by 4.8% during the third quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock worth $66,802,000 after purchasing an additional 84,760 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. BMO Capital Markets started coverage on shares of Dyne Therapeutics in a research report on Wednesday. They set an “outperform” rating and a $50.00 price target on the stock. Chardan Capital reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday, February 28th. Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Finally, Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and an average price target of $48.85.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.